VOR250117C7500
- 0.05
- 0.000.00%
Vor Biopharma Newsroom
Vor Biopharma Price Target Maintained With a $12.00/Share by JMP Securities
Oppenheimer Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $8
Vor Biopharma Reports Promising Phase 1/2 Study Results
Stifel Nicolaus Remains a Buy on Vor Biopharma (VOR)
Vor Bio Presents Data on AML Therapy at ASH 2024 Annual Meeting
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback From FDA Regarding Registrational Trial Design
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Recursion Pharmaceuticals (RXRX) and AN2 Therapeutics, Inc. (ANTX)
Vor Bio to Participate in the Stifel 2024 Healthcare Conference
Vor Biopharma's Trem-cel Therapy Shows Promise With Positive Patient Dosing and Upcoming Data Presentation
Vor Biopharma Is Maintained at Outperform by Baird
HC Wainwright & Co. Reiterates Buy on Vor Biopharma, Maintains $17.5 Price Target
Vor Biopharma Analyst Ratings
Barclays Maintains Vor Biopharma(VOR.US) With Buy Rating, Maintains Target Price $3
Barclays Keeps Their Buy Rating on Vor Biopharma (VOR)
Express News | Vor Biopharma Inc : Baird Cuts Target Price to $14 From $22
Vor Biopharma Q3 EPS $(0.40), Inline
Express News | Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
Press Release: Vor Bio Reports Third Quarter 2024 Financial Results and Provides Company Update
Vor Biopharma | 10-Q: Q3 2024 Earnings Report
12 Health Care Stocks Moving In Monday's After-Market Session